2.77

1.60% -0.045

After Hours: 2.76 -0.01 -0.36%

Lisata Therapeutics Inc (LSTA)

Overview News Price History Financials Discussions Forecast Stock Split

Lisata Therapeutics Inc stock is currently priced at $2.77, with a 24-hour trading volume of 8,831. It has seen a -1.60% decreased in the last 24 hours and a -0.36% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $2.81 pivot point. If it approaches the $2.66 support level, significant changes may occur.

Previous Close:

$2.815

Open:

$2.92

24h Volume:

8,831

Market Cap:

$23.01M

Revenue:

Net Income/Loss:

$-20.84M

P/E Ratio:

-0.2796

EPS:

-9.9082

Net Cash Flow:

$-20.03M

1W Performance:

-6.10%

1M Performance:

-0.36%

6M Performance:

+19.91%

1Y Performance:

-29.91%

1D Range:

$2.7351

$2.9449

52W Range:

$1.95

$4.5329

Lisata Therapeutics Inc Stock (LSTA) Company Profile

Name

Lisata Therapeutics Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

908 842 0100

Address

110 Allen Road, 2nd Floor, Basking Ridge

Employee

Twitter

Next Earnings Date

2024-06-13

Latest SEC Filings

LSTA's Discussions on Twitter

Lisata Therapeutics Inc Stock (LSTA) Latest News

Lisata Therapeutics, Inc. (NASDAQ:LSTA) Short Interest Update - Defense World

Defense World

Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results - Marketscreener.com

Marketscreener.com

Earnings call: Lisata Therapeutics reports Q1 progress on cancer drug By Investing.com - Investing.com

Investing.com

Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results - Proactive Investors Australia

Proactive Investors Australia

Earnings call: Lisata Therapeutics reports Q1 progress on cancer drug - Investing.com

Investing.com

Lisata Therapeutics Net Loss Declines From a Year Earlier - Yahoo Finance

Yahoo Finance

Lisata Therapeutics Inc Stock (LSTA) Financials Data

Lisata Therapeutics Inc (LSTA) Net Income 2024

LSTA net income (TTM) was -$20.84 million for the quarter ending December 31, 2023, a +61.57% increase year-over-year.

Lisata Therapeutics Inc (LSTA) Cash Flow 2024

LSTA recorded a free cash flow (TTM) of -$20.03 million for the quarter ending December 31, 2023, a +6.63% increase year-over-year.

Lisata Therapeutics Inc (LSTA) Earnings per Share 2024

LSTA earnings per share (TTM) was -$2.58 for the quarter ending December 31, 2023, a +77.22% growth year-over-year.

Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.